Companies: 10,795·Total market cap: $144.5T
Provention Bio, Inc.

Provention Bio, Inc.

PRVBNASDAQHealthcare
$24.98
+$0.00(+0.00%)
Market Cap$2.4B
P/E Ratio—
52W High$25.0
52W Low$3.185
Cash on HandFinancialsRevenue

Provention Bio, Inc. (PRVB) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

PRVB · cash on hand · updated Dec 31, 2022

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$165.0M▲ +29.8% vs prior year
FY · as of Dec 31, 2022 · Reported in USD
Cash & Cash Equiv. (CCE)
$44.0M
cashAndCashEquivalents
Short-Term Investments
$121.0M
shortTermInvestments
YoY Change vs Prior Year
+29.8%
vs prior fiscal year
Latest Quarter
$165.0M
Q4 2022
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2022

Net cash vs debt

Cash & ST Investments$165.0MCash on Hand
Total Debt$23.9MTotal Debt
Net Cash / Net Debt+$141.1MNet Cash Position
Cash vs Debt Ratio
Cash 87%Debt 13%

Provention Bio, Inc. has a net cash position of $141.1M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$165.0M − $23.9M = +$141.1M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
PRVB annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2022Latest$165.0M+29.8%
Dec 31, 2021$127.1M+4.4%
Dec 31, 2020$121.8M+42.7%
Dec 31, 2019$85.4M+45.8%
Dec 31, 2018$58.5M+168.1%
PRVB cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Provention Bio, Inc.
Provention Bio, Inc.YOU
PRVB
$165.0M7.0%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Provention Bio, Inc. (PRVB) cash on hand as of December 31, 2022 is $165.0M, comprising $44.0M in cash and cash equivalents (CCE) plus $121.0M in short-term investments — reported as Provention Bio, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Provention Bio, Inc. cash reserves or cash position.

Provention Bio, Inc. annual cash on hand history shows increased +29.8% in 2022: increased +29.8% in 2022. Provention Bio, Inc. cash reserves in 2022 reflect the company's capital allocation strategy.

Provention Bio, Inc. carries total debt of $23.9M against cash of $165.0M, resulting in a net cash position of +$141.1M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

PRVB cash on hand · 5 questions

As of December 31, 2022, Provention Bio, Inc. (PRVB) has $165,003,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $44,039,000 in cash and cash equivalents (CCE) plus $120,964,000 in short-term investments. Latest quarter (December 31, 2022): $165,003,000. Data sourced from the annual 10-K filing via FMP.

PRVB cash on handPRVB cash reservesPRVB cash 2022how much cash does PRVB have

▸ Source: FMP /balance-sheet-statement · US GAAP · Provention Bio, Inc. · Provention Bio, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2022